Molecular Partners AG (SWX:MOLN)
2.500
-0.010 (-0.40%)
Nov 12, 2026, 12:10 PM CET
Molecular Partners AG Employees
Molecular Partners AG had 134 employees as of December 31, 2025. The number of employees decreased by 25 or 15.46% compared to the previous year. That makes Molecular Partners AG the 29,627th largest employer in the world and 169th in Switzerland.
Employees
134
Change (1Y)
-25
Growth (1Y)
-15.46%
Revenue / Employee
n/a
Profits / Employee
-381.04K CHF
Market Cap
95.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 134 | -25 | -15.46% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bachem Holding AG | 2,725 |
| Idorsia | 487 |
| Basilea Pharmaceutica AG | 200 |
| Santhera Pharmaceuticals Holding AG | 94 |
| BioVersys AG | 38 |
| Newron Pharmaceuticals | 27 |
| Xlife Sciences AG | 20 |
| Addex Therapeutics | 3 |
Molecular Partners AG News
- 6 days ago - Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026 - GlobeNewsWire
- 7 days ago - Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026 - GlobeNewsWire
- 14 days ago - Molecular Partners AG Earnings release: Q3 2026 - Filings
- 14 days ago - Molecular Partners AG Slides: Q3 2026 - Filings
- 14 days ago - Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy - GlobeNewsWire
- 2 months ago - Molecular Partners AG Slides: Q2 2026 - Filings
- 2 months ago - Molecular Partners AG Earnings release: Q2 2026 - Filings
- 2 months ago - Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study - GlobeNewsWire